MX394213B - Métodos de sedación y formulación parenteral para uso durante el tratamiento de cuidados críticos. - Google Patents
Métodos de sedación y formulación parenteral para uso durante el tratamiento de cuidados críticos.Info
- Publication number
- MX394213B MX394213B MX2018001720A MX2018001720A MX394213B MX 394213 B MX394213 B MX 394213B MX 2018001720 A MX2018001720 A MX 2018001720A MX 2018001720 A MX2018001720 A MX 2018001720A MX 394213 B MX394213 B MX 394213B
- Authority
- MX
- Mexico
- Prior art keywords
- critical care
- use during
- care treatment
- parenteral formulation
- during critical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Anesthesiology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562203731P | 2015-08-11 | 2015-08-11 | |
| US201562203748P | 2015-08-11 | 2015-08-11 | |
| US14/834,027 US9399034B1 (en) | 2015-08-11 | 2015-08-24 | Methods of sedation during critical care treatment |
| US15/185,650 US9717716B2 (en) | 2015-08-11 | 2016-06-17 | Methods of sedation during critical care treatment |
| PCT/US2016/045094 WO2017027249A1 (en) | 2015-08-11 | 2016-08-02 | Methods of sedation and parenteral formulation for use during critical care treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018001720A MX2018001720A (es) | 2018-09-06 |
| MX394213B true MX394213B (es) | 2025-03-24 |
Family
ID=59687449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018001720A MX394213B (es) | 2015-08-11 | 2016-08-02 | Métodos de sedación y formulación parenteral para uso durante el tratamiento de cuidados críticos. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20180235942A1 (enExample) |
| EP (1) | EP3334427A4 (enExample) |
| JP (1) | JP6857647B2 (enExample) |
| KR (1) | KR20180048707A (enExample) |
| CN (1) | CN108135889A (enExample) |
| AU (1) | AU2016304737B2 (enExample) |
| CA (1) | CA2994952A1 (enExample) |
| CO (1) | CO2018002534A2 (enExample) |
| IL (1) | IL257296B2 (enExample) |
| MX (1) | MX394213B (enExample) |
| PE (1) | PE20181332A1 (enExample) |
| TW (1) | TWI763632B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4541420A3 (en) | 2015-07-17 | 2025-06-25 | Ovid Therapeutics Inc. | Methods of treating developmental disorders with gaboxadol |
| JP2019524816A (ja) | 2016-08-11 | 2019-09-05 | オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | てんかん性障害の処置のための方法および組成物 |
| US10071083B2 (en) | 2017-02-03 | 2018-09-11 | Ovid Therapeutics Inc | Use of gaboxadol in the treatment of tinnitus |
| CA3113644A1 (en) | 2018-09-20 | 2020-03-26 | Ovid Therapeutics Inc. | Use of gaboxadol for the treatment of tourette syndrome, tics and stuttering |
| JP2022514194A (ja) | 2018-11-21 | 2022-02-10 | セルテゴ セラピューティクス インコーポレイテッド | 自殺のリスクを低減し、うつ病を迅速に軽減するためのガボキサドール |
| MX2021007224A (es) | 2018-12-17 | 2021-09-23 | Ovid Therapeutics Inc | Uso de gaboxadol para el tratamiento del trastorno del sue?o vigilia que no es de 24 horas. |
| EP4153549A2 (en) | 2020-05-20 | 2023-03-29 | Certego Therapeutics Inc. | Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders |
| US20220218740A1 (en) * | 2020-10-25 | 2022-07-14 | Vaporworks Nursing Anesthesia Inc. | Opioid-free compositions for anesthesiological applications and related methods and systems |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6071933A (en) * | 1999-12-03 | 2000-06-06 | Diversified Medical Innovations, Inc. | Homogeneous remifentanil-propofol blend for patient controlled anesthesia and process for its use |
| WO2005063248A1 (en) * | 2003-12-22 | 2005-07-14 | Sepracor Inc. | Modafinil combination therapy for improving sleep quality |
| ES2337700T3 (es) * | 2004-02-18 | 2010-04-28 | Sepracor, Inc. | Terapia combinada de agonista de dopamina con sedantes para mejorar la calidad del sueño. |
| US20090143335A1 (en) * | 2007-10-29 | 2009-06-04 | H. Lundbeck A/S | Modified absorption formulation of gaboxadol |
| US9399034B1 (en) * | 2015-08-11 | 2016-07-26 | Ovid Therapeutics Inc | Methods of sedation during critical care treatment |
-
2016
- 2016-08-02 CA CA2994952A patent/CA2994952A1/en active Pending
- 2016-08-02 US US15/751,680 patent/US20180235942A1/en not_active Abandoned
- 2016-08-02 EP EP16835628.5A patent/EP3334427A4/en not_active Withdrawn
- 2016-08-02 CN CN201680059253.3A patent/CN108135889A/zh active Pending
- 2016-08-02 PE PE2018000199A patent/PE20181332A1/es not_active Application Discontinuation
- 2016-08-02 MX MX2018001720A patent/MX394213B/es unknown
- 2016-08-02 KR KR1020187007146A patent/KR20180048707A/ko not_active Withdrawn
- 2016-08-02 JP JP2018506932A patent/JP6857647B2/ja not_active Expired - Fee Related
- 2016-08-02 AU AU2016304737A patent/AU2016304737B2/en not_active Ceased
- 2016-08-10 TW TW105125498A patent/TWI763632B/zh not_active IP Right Cessation
-
2018
- 2018-02-01 IL IL257296A patent/IL257296B2/en unknown
- 2018-03-09 CO CONC2018/0002534A patent/CO2018002534A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016304737A1 (en) | 2018-02-22 |
| IL257296B2 (en) | 2023-02-01 |
| TWI763632B (zh) | 2022-05-11 |
| EP3334427A1 (en) | 2018-06-20 |
| MX2018001720A (es) | 2018-09-06 |
| CO2018002534A2 (es) | 2018-05-31 |
| AU2016304737B2 (en) | 2021-03-11 |
| IL257296B (en) | 2022-10-01 |
| PE20181332A1 (es) | 2018-08-20 |
| CA2994952A1 (en) | 2017-02-16 |
| EP3334427A4 (en) | 2019-02-06 |
| CN108135889A (zh) | 2018-06-08 |
| JP2018522920A (ja) | 2018-08-16 |
| JP6857647B2 (ja) | 2021-04-14 |
| US20180235942A1 (en) | 2018-08-23 |
| TW201717944A (zh) | 2017-06-01 |
| IL257296A (en) | 2018-03-29 |
| KR20180048707A (ko) | 2018-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX394213B (es) | Métodos de sedación y formulación parenteral para uso durante el tratamiento de cuidados críticos. | |
| CY1124368T1 (el) | Μεθοδοι αυξησης της τονικης αναστολης και θεραπειας του συνδρομου angelman | |
| CY1125326T1 (el) | Προαιρετικως συντηγμενα ετεροκυκλυλο- υποκατεστημενα παραγωγα πυριμιδινης χρησιμα για τη θεραπευτικη αγωγη φλεγμονωδων, μεταβολικων, ογκολογικων και αυτοανοσων ασθενειων. | |
| PH12017501046A1 (en) | Azabicyclooctane derivatives as fxr agonists for use in the treatment of liver and gastrointestinal diseases | |
| MX378273B (es) | Compuestos activos hacia bromodominios. | |
| PL3381451T3 (pl) | Kompozycja farmaceutyczna stosowana do redukcji zlokalizowanej tkanki tłuszczowej i zastosowanie kompozycji farmaceutycznej | |
| NZ729252A (en) | Methyl-and trifluoromethyl-substituted pyrrolopyridine modulators of rorc2 and methods of use thereof | |
| IL285440A (en) | Oral compositions containing octreotide in combination with other therapeutic agents for tretment of acromegaly | |
| CL2015002897A1 (es) | Inhibidores de bace1 | |
| HUE058151T2 (hu) | Enterococcusból származó flagellin készítményei terápiában történõ alkalmazásra | |
| CY1122971T1 (el) | Ενωσεις διυδροπυριμιδιν-2-ονης και ιaτρικη χρηση αυτων | |
| CY1120573T1 (el) | Παραγωγα πυριδαζινης για χρηση στην προληψη ή θεραπεια αταξικης διαταραχης | |
| PL3732294T3 (pl) | Tymohydrochinon do stosowania w leczeniu hiperglikemii | |
| DOP2016000297A (es) | Composiciones farmacéuticas útiles para tratar enfermedades infecciosas | |
| MA50358A (fr) | Sémaglutide en thérapie médicale | |
| CY1119532T1 (el) | (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη | |
| CY1121566T1 (el) | Νευροπροστατευτικο και ενδειξη αυτου | |
| PT3215143T (pt) | Combinação compreendendo espirulina e palmitoíletanolamida | |
| CY1119522T1 (el) | (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη | |
| SMT202300244T1 (it) | Inibitori di pi3k p-delta 110 per uso nell’erogazione di virus nel trattamento di cancro | |
| IT201700124249U1 (it) | Apparecchiatura portatile per la somministrazione di una miscela di gas nella rianimazione cardiopolmonare di un paziente | |
| MX391447B (es) | Tratamiento de los sintomas asociados a terapia privacion de androgenos. | |
| IL248428B (en) | 3,1-propanedisulfonic acid or its pharmaceutically acceptable salt for use in the treatment of sarcoidosis | |
| MX2018001575A (es) | Compuestos triciclicos y su uso en el tratamiento del cancer. | |
| AR095890A1 (es) | Uso de ácido trifluoroacético y sales del mismo para tratar la hipercolesterolemia |